Novocure Announces Clinical Collaboration with MSD on a Registrational-Intent Study to Evaluate Tumor Treating Fields Together with KEYTRUDA^® (pembrolizumab) in Newly Diagnosed Glioblastoma

Novocure announced it has entered into a clinical trial collaboration agreement with MSD, a tradename of Merck & Co., Inc. to study the use of Tumor Treating Fields concomitant with MSD’s anti-PD-1 therapy KEYTRUDA® for the treatment of patients with newly diagnosed glioblastoma.